Shanghai Junshi Biosciences Co.Ltd(688180) : vv116 is used for the early treatment of mild to moderate covid-19, reaching the primary endpoint preset by the clinical protocol

Financial Associated Press, May 23, Shanghai Junshi Biosciences Co.Ltd(688180) announcement, The product of oral nucleoside anti SARS cov-2 drug vv116 tablets (project code: jt001/vv116, referred to as “vv116”) jointly developed by the holding subsidiary Shanghai juntuo Biomedical Technology Co., Ltd. (“juntuo biology”) and Suzhou Wangshan wangshui biomedical Co., Ltd. (“Wangshan wangshui”) is used for the treatment of mild to moderate novel coronavirus pneumonia (“covid-19”) with benamavir tablets / ritonavir tablets (paxlovid) The phase III registered clinical study of early treatment (nct05341609) reached the primary endpoint preset by the protocol. The company will communicate with the regulatory authorities on the submission of new drug listing applications in the near future.